NEW DELHI: India’s General Narcotics Control (DCHOLD) asked WHO to share more details about the primary illness, the signs and symptoms, and the treatment provided to Gambian children who is presumed dead after consuming contaminated cough syrup sold by a Indian pharmaceutical company.
The clinical characteristics and treatments that children receive as shared by WHO so far are not sufficient to determine the cause of the disease (cause of death), DCGI said in an email to representatives of the WHO. WHO. This follows the first meeting of the technical expert committee established by the Union Health Ministry to review and analyze the details of the adverse events and all relevant details of the death. series shared by the United Nations agency.
According to the DCGI, the committee has observed that the information provided by WHO to date is insufficient to draw conclusions. The committee has said that the UN agency needs to provide detailed information about the underlying illness, signs and symptoms, treatments received before and after admission, and the names and brands of drug formulations. used in the treatment before and after admission, their manufacturer and shelf life among others. It also sought a verbal autopsy report.
The clinical characteristics and treatments that children receive as shared by WHO so far are not sufficient to determine the cause of the disease (cause of death), DCGI said in an email to representatives of the WHO. WHO. This follows the first meeting of the technical expert committee established by the Union Health Ministry to review and analyze the details of the adverse events and all relevant details of the death. series shared by the United Nations agency.
According to the DCGI, the committee has observed that the information provided by WHO to date is insufficient to draw conclusions. The committee has said that the UN agency needs to provide detailed information about the underlying illness, signs and symptoms, treatments received before and after admission, and the names and brands of drug formulations. used in the treatment before and after admission, their manufacturer and shelf life among others. It also sought a verbal autopsy report.
